Overall Survival with Osimertinib in Resected <i>EGFR</i>-Mutated NSCLC-Reference-Cited by-同舟云学术

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC

Published:2023-07-13 Issue:2 Volume:389 Page:137-147
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Tsuboi Masahiro¹,Herbst Roy S.¹,John Thomas¹,Kato Terufumi¹,Majem Margarita¹,Grohé Christian¹,Wang Jie¹,Goldman Jonathan W.¹^ORCID,Lu Shun¹,Su Wu-Chou¹,de Marinis Filippo¹,Shepherd Frances A.¹,Lee Ki Hyeong¹,Le Nhieu Thi¹,Dechaphunkul Arunee¹,Kowalski Dariusz¹,Poole Lynne¹,Bolanos Ana¹,Rukazenkov Yuri¹,Wu Yi-Long¹

Affiliation:

1. From the Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa (M.T.), the Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama (T.K.) — both in Japan; the Section of Medical Oncology, Yale School of Medicine and Yale Cancer Center, New Haven, CT (R.S.H.); the Department of Medical Oncology, Peter MacCallum Cancer Centre, and the Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia (T.J.); the Department of...

Funder

AstraZeneca

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2304594

Reference38 articles.

1. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update

2. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I-IIIA Completely Resected Non–Small-Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update

3. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up